Microplasmin meets Phase III endpoint

ThromboGenics N.V. (Euronext:THR) said a single intravitreal injection of microplasmin met the primary endpoint vs. placebo in the Phase III TG-MV-007 trial to treat focal vitreomacular adhesion (VMA). Microplasmin significantly increased the proportion of patients achieving non-surgical resolution of their focal VMA as measured by optical coherence tomography at day 28 vs. placebo. The double-blind, international trial enrolled 326 patients. Data were presented at the American Society of Retina Specialists meeting in Vancouver. The product is a recombinant microplasmin, a truncated form of the natural human protein plasmin. ...